10-Year Evaluation of Adherence and Satisfaction with Information about Tolvaptan in ADPKD: A Single-Center Pilot Study

PURPOSE: Tolvaptan is the only approved drug for the treatment of autosomal dominant polycystic kidney disease (ADPKD) and causes significant polyuria with secondary polydipsia. Up to now, there is no study that examines tolvaptan adherence and satisfaction with information received about tolvaptan...

Descripción completa

Detalles Bibliográficos
Autores principales: Schirutschke, Holger, Gross, Peter, Paliege, Alexander, Hugo, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8427080/
https://www.ncbi.nlm.nih.gov/pubmed/34511889
http://dx.doi.org/10.2147/PPA.S325738

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8427080/
https://www.ncbi.nlm.nih.gov/pubmed/34511889
http://dx.doi.org/10.2147/PPA.S325738

Ejemplares similares